Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach.
Regan C, Scierka L, Dardik A, Tonnessen B, Iyad Ochoa Chaar C, Ionescu C, Aboian E, Cardella J, Nassiri N, Guzman R, Attaran R, Nagpal S, Shah S, Smolderen K, Mena-Hurtado C. Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach. Vascular 2024, 17085381241246318. PMID: 38669051, DOI: 10.1177/17085381241246318.Peer-Reviewed Original ResearchDual antiplatelet therapyPeripheral arterial diseaseCYP2C19 testingCYP2C19 mutationsHeterogeneity of treatment effectsPeripheral vascular interventionsConsensus statementKnowledge questionsAntiplatelet therapyGenetic testingVascular surgeryAcademic health systemBarriers to implementationInterquartile rangeCYP2C19 genotype testingVascular diseaseInterventional cardiologyModified Delphi methodPatient's metabolic statusManagement of patientsCritical limb ischemiaPerceived barriersPeripheral vascular diseaseArterial vascular diseaseClinician perspectivesRepresentation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years
Kostiuk V, Thaxton C, Loh S, Cardella J, Dardik A, Tonnessen B. Representation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years. JVS-Vascular Insights 2024, 2: 100077. DOI: 10.1016/j.jvsvi.2024.100077.Peer-Reviewed Original ResearchClinical trialsFemale vascular surgeonsVascular surgeonsMethods Clinical trialsArtery diseaseClinical trial leadershipSite principal investigatorsVascular conditionsAbdominal aortic aneurysmSurgeon-investigatorInvestigator-led trialsCarotid artery diseasePeripheral arterial diseaseCarotid diseaseProportion of womenVenous thrombectomyBoard certificationAortic aneurysmPercentage of womenIndustry-sponsored trialsTrial leadershipHemodialysis accessSubgroup analysisVascular surgerySurgeons